Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

Figure 2

Probability of overall survival (A) and the time to progression (B) according to Child-Pugh classification of cirrhosis. The median overall survival of the HCC patients with Child-Pugh A cirrhosis was significantly longer compared with that of the HCC patients with Child-Pugh B cirrhosis (186 days vs 64 days, P = 0.004), although the median time to tumor progression did not differ between the two groups (104 days vs 63 days, P = 0.154).

Back to article page